The New England Journal of Medicine August 26, 1999

Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Judith S. Hochman, Lynn A. Sleeper, John G. Webb, Timothy A. Sanborn, et al. (SHOCK Investigators)

Bottom Line

In patients with acute myocardial infarction complicated by cardiogenic shock, early revascularization did not significantly reduce 30-day mortality compared to medical stabilization, but it demonstrated a significant and clinically meaningful survival benefit at 6 months.

Key Findings

1. At 30 days (the primary endpoint), all-cause mortality was 46.7% in the early revascularization group compared to 56.0% in the medical-therapy group, a difference that did not reach statistical significance (absolute difference, -9.3%; 95% CI, -20.5 to 1.9%; P=0.11).

2. At 6 months (secondary endpoint), mortality was significantly lower in the early revascularization group than in the medical therapy group (50.3% vs. 63.1%; P=0.027).

3. Intra-aortic balloon counterpulsation (IABP) was utilized aggressively, being deployed in 86% of patients in both treatment arms.

4. In the invasive strategy arm, 97% of patients underwent early coronary angiography and 87% successfully underwent revascularization (either PCI or CABG).

5. The median time to the onset of cardiogenic shock was 5.6 hours after the index infarction.

Study Design

Design

Multicenter RCT

Open-Label

Sample

302

Patients

Duration

6 mo

Median

Setting

Multicenter, International

Population Patients with acute myocardial infarction complicated by cardiogenic shock resulting from predominant left ventricular failure.

Intervention Emergency revascularization (percutaneous transluminal coronary angioplasty or coronary-artery bypass grafting) combined with intensive medical support.

Comparator Initial medical stabilization (including thrombolytic therapy and intra-aortic balloon pumping), with delayed revascularization permitted only if clinically appropriate.

Outcome All-cause mortality at 30 days.

Study Limitations

• The trial failed to achieve statistical significance for its primary endpoint (30-day mortality), meaning the justification for the intervention relied heavily on the secondary 6-month survival data.

• The open-label design, while unavoidable for testing an invasive surgical/interventional procedure against medical management, inherently introduces performance and ascertainment biases.

• The extremely high rate of IABP use (86%) reflects the standard of care in the 1990s, making the background medical therapy less representative of modern practice, especially post-IABP-SHOCK II.

• Recruitment for cardiogenic shock trials is notoriously challenging; strict inclusion criteria and need for rapid consent may have introduced selection bias, limiting the generalizability to all real-world patients presenting in extremis.

Clinical Significance

The SHOCK trial was a paradigm-shifting landmark in cardiovascular medicine. Despite technically missing its 30-day primary endpoint, the divergence of the survival curves at 6 months proved that mechanically addressing the underlying ischemia is critical. This trial fundamentally changed global guidelines, establishing emergent coronary angiography and early revascularization (PCI or CABG) as a Class I recommendation for patients presenting with AMI complicated by cardiogenic shock.

Historical Context

Prior to the publication of the SHOCK trial, mortality rates for acute myocardial infarction complicated by cardiogenic shock were staggeringly high, frequently approaching 70-80%. The dominant strategy was medical stabilization utilizing thrombolytic therapy and inotropes. However, thrombolytics rely on adequate coronary perfusion pressure to reach the clot, rendering them largely ineffective in the hypotensive state of cardiogenic shock. The SHOCK trial was the first major randomized controlled trial to systematically challenge this conservative approach, demonstrating that an early invasive strategy could salvage the myocardium and drastically improve mid-to-long-term survival.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the pathophysiological 'spiral' of cardiogenic shock in the setting of acute myocardial infarction, and how does early revascularization aim to interrupt this cycle more effectively than medical therapy with vasopressors?

Key Response

This question tests foundational knowledge of the shock spiral: myocardial ischemia leads to decreased contractility and cardiac output, causing hypotension, which further reduces coronary perfusion pressure and exacerbates ischemia. Early revascularization directly addresses the root cause by restoring blood flow, whereas vasopressors and inotropes, though necessary for immediate stabilization, often increase myocardial oxygen demand and can worsen the underlying ischemia.

Resident

Given that the SHOCK trial showed no statistically significant mortality benefit at 30 days but a significant benefit at 6 months, how do you frame your clinical decision-making and family counseling when sending an unstable AMI-shock patient to the cath lab?

Key Response

Residents must learn to apply trial data to clinical communication. The rationale is that early revascularization provides a delayed but profound survival benefit by salvaging myocardium that dictates long-term recovery. In the acute phase (first 30 days), mortality remains highly driven by established multiorgan failure and systemic inflammatory response syndrome (SIRS), which revascularization cannot instantly reverse. Counseling should reflect high immediate risk but improved long-term hope.

Fellow

In the SHOCK trial, the pre-specified subgroup analysis suggested that elderly patients (older than 75 years) did not benefit from early revascularization. How should this finding influence your real-world decision to activate the cath lab for an elderly patient presenting with STEMI and cardiogenic shock?

Key Response

This explores the nuances of subgroup analyses and subsequent data evolution. While the original trial suggested no benefit for those >75, the study was severely underpowered for this subgroup. Later data from the SHOCK registry and subsequent trials demonstrated that selected elderly patients with favorable physiological age do benefit. Fellows must weigh chronological versus physiological age and understand the limitations of underpowered subgroup analyses.

Attending

The SHOCK trial technically missed its primary endpoint of 30-day mortality (p=0.11), yet it is universally taught as a landmark, practice-changing study. As an attending teaching evidence-based medicine, how do you justify the adoption of early revascularization as a standard of care despite the statistical failure of the primary endpoint?

Key Response

Attendings must teach the broader context of EBM beyond just the primary p-value. The justification relies on the biological plausibility, the significant divergence of survival curves at 6 months (p=0.027), an absolute risk reduction of 13.2 lives saved per 100 treated at 1 year, and the historical context where alternative medical therapies yielded >80% mortality. It highlights the importance of clinical significance and long-term follow-up in critical care trials.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The SHOCK trial suffered from slow enrollment and was ultimately underpowered for its initial sample size target for the 30-day primary endpoint. From a methodological perspective, how does substantial crossover from the medical arm to delayed revascularization affect the intention-to-treat (ITT) analysis, and what alternative statistical designs could mitigate these issues in future critical care trials?

Key Response

Crossover from the medical arm to the revascularization arm biases the ITT analysis toward the null, potentially causing a Type II error for the 30-day endpoint. A methodology expert would critique the reliance on pure ITT in high-crossover scenarios and discuss per-protocol or as-treated sensitivity analyses. Furthermore, Bayesian adaptive trial designs or sequential group designs could be proposed to better handle slow enrollment and shifting effect sizes over time.

Journal Editor

As a peer reviewer evaluating the SHOCK manuscript, how would you address the high rate of Intra-Aortic Balloon Pump (IABP) utilization (86%) in both study arms, and what threats does this pose to the external validity of the study's conclusions regarding revascularization alone?

Key Response

An editor would flag that the intervention tested was effectively 'early revascularization PLUS routine IABP' versus 'medical stabilization PLUS routine IABP.' The critical appraisal focuses on whether the benefit of revascularization is dependent on this specific adjunctive mechanical support. This threat to external validity is highly relevant today, as routine IABP use is no longer standard practice based on the IABP-SHOCK II trial, meaning modern outcomes might differ.

Guideline Committee

Early revascularization received a Class 1 recommendation in ACC/AHA guidelines for AMI complicated by cardiogenic shock based heavily on this trial. However, given that multivessel disease is common in this population, how should guidelines reconcile the original SHOCK trial findings with more recent evidence (such as the CULPRIT-SHOCK trial) regarding the extent of revascularization during the index procedure?

Key Response

Guideline committees must continuously synthesize evolving evidence. The SHOCK trial established the overarching principle of early revascularization. However, CULPRIT-SHOCK later demonstrated that culprit-lesion-only PCI is superior to immediate multivessel PCI in cardiogenic shock. The rationale must address updating guidelines to maintain the Class 1 recommendation for early revascularization while providing new, specific constraints (Class 3 for routine immediate multivessel PCI) based on modern trials.

Clinical Landscape

Noteworthy Related Trials

2012

IABP-SHOCK II Trial

n = 600 · NEJM

Tested

Intraaortic balloon pump (IABP)

Population

Patients with acute myocardial infarction complicated by cardiogenic shock

Comparator

No IABP (medical therapy alone)

Endpoint

30-day all-cause mortality

Key result: The use of an intraaortic balloon pump did not significantly reduce 30-day mortality compared to medical therapy alone.

2017

CULPRIT-SHOCK Trial

n = 706 · NEJM

Tested

Culprit-lesion-only PCI

Population

Patients with AMI and multivessel coronary artery disease complicated by cardiogenic shock

Comparator

Immediate multivessel PCI

Endpoint

30-day composite of death or severe renal failure leading to renal-replacement therapy

Key result: Culprit-lesion-only PCI significantly reduced the risk of the primary composite endpoint compared to immediate multivessel PCI.

2023

ECLS-SHOCK Trial

n = 420 · NEJM

Tested

Extracorporeal life support (ECLS/VA-ECMO)

Population

Patients with AMI complicated by cardiogenic shock with planned early revascularization

Comparator

Standard medical therapy (no ECLS)

Endpoint

30-day all-cause mortality

Key result: Routine use of ECLS did not reduce 30-day mortality and was associated with a higher risk of moderate or severe bleeding compared to standard medical therapy.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis